other material
confidence high
sentiment neutral
materiality 0.30
Sigyn Therapeutics reports conversion of convertible debentures into 1,243,000 common shares
Sigyn Therapeutics, Inc.
- On June 2, 2023, $16,500 debenture converted into 33,000 shares at $0.50 per share.
- Also on June 2, 2023, $181,500 of other debentures converted into 1,210,000 shares at $0.15 per share.
- Outstanding shares increased from 42,981,659 to 44,224,659 as a result of these conversions.
- Remaining convertible debentures total $970,200 aggregate principal due through March 2024.